➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim
Harvard Business School

Last Updated: October 23, 2021

DrugPatentWatch Database Preview

Agalsidase beta - Biologic Drug Details

Email this page to a colleague

« Back to Dashboard

Summary for agalsidase beta
Suppliers: see list1
Recent Clinical Trials: See clinical trials for agalsidase beta
Recent Clinical Trials for agalsidase beta

Identify potential brand extensions & biosimilar entrants

SanofiPhase 4
University Hospital, RouenN/A
Amicus TherapeuticsPhase 2

See all agalsidase beta clinical trials

Pharmacology for agalsidase beta
Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. General brand-side disclosures
  4. These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for agalsidase beta Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for agalsidase beta Derived from Company Disclosures

These patents were obtained from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Patent No. Estimated Patent Expiration Source
Genzyme Corporation FABRAZYME agalsidase beta For Injection 103979 ⤷  Try it Free 2039-02-26 Company disclosures
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Patent No. >Estimated Patent Expiration >Source

3) Low Certainty: US Patents for agalsidase beta Derived from Patent Text Search

These patents were obtained by searching patent claims

Supplementary Protection Certificates for agalsidase beta

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
122013000092 Germany ⤷  Try it Free PRODUCT NAME: AGALSIDASE BETA; REGISTRATION NO/DATE: EU/1/01/188/001-006 20010803
132013902212169 Italy ⤷  Try it Free AUTHORISATION NUMBER(S) AND DATE(S): EU/1/01/188, 20010803;EU/1/01/188/001-002-003, 20010803
300452 Netherlands ⤷  Try it Free PRODUCT NAME: AGALSIDASE ALFA; REGISTRATION NO/DATE: EU/1/01/189/001 20010807
CA 2010 00020 Denmark ⤷  Try it Free
SZ 20/2010 Austria ⤷  Try it Free PRODUCT NAME: AGALSIDASE ALPHA
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.